查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990250

胃腸道藥物市場：按產品類型、給藥途徑和分銷管道分類的全球市場預測，2026-2032年

Gastrointestinal Agents Market by Product Type, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年，消化器官系統藥物市場價值為631.2億美元，預計到2026年將成長至661.5億美元，複合年成長率為5.13%，到2032年將達到896.4億美元。

主要市場統計數據
基準年 2025 631.2億美元
預計年份：2026年 661.5億美元
預測年份 2032 896.4億美元
複合年成長率 (%) 5.13%

簡要概述目前影響消化器官系統藥物開發和分銷的臨床因素、商業性趨勢和策略重點。

消化器官系統藥物市場正受到多種因素的共同影響而不斷發展：臨床實踐的改變、患者期望的提高以及科學的快速進步。本執行摘要全面概述了影響消化器官系統治療領域產品開發、商業化和供應鏈管理決策的治療領域、臨床因素和商業性趨勢。

科學進步、數位醫療模式、監管監督和基於價值的支付趨勢如何共同作用，重塑治療重點、商業模式和價值鏈策略。

消化器官系統藥物領域正經歷著由科學、病患期望和不斷發展的醫療服務模式所驅動的變革。我們對腸道微生物組和宿主-微生物相互作用的理解不斷加深，使得益生菌、益生元和標靶微生物組療法從輔助性治療躍升為治療探索的核心要素。同時，精準醫療方法正將基於生物標記的治療選擇納入到以往主要關注症狀控制的討論中。

本研究評估了美國關稅政策的調整如何影響消化器官系統藥物供應鏈中的採購決策、製造韌性和跨部門合作。

2025年的關稅環境對醫藥原料和成品藥都產生了影響，對產業相關人員而言，這是一個重要的策略轉捩點。影響活性成分、輔料、包裝材料和成品製​​劑的關稅調整正在影響採購決策、利潤率管理和採購地點。各公司正在透過重新評估供應商組合、加快二級資訊認證流程以及增加緩衝庫存來應對這一變化，從而緩解採購波動。

詳細的細分洞察揭示了產品類型、給藥途徑和分銷管道的差異如何決定臨床定位、配方策略和商業性執行。

市場區隔能夠驅動精準的市場策略，並明確臨床差異化與商業性機會的交會點。根據產品類型，市場涵蓋急性症狀類藥物（如制酸劑和止吐藥）、針對運動和分泌功能的治療類藥物（如H2受體拮抗劑和質子幫浦阻斷劑）以及輔助類藥物（包括瀉藥以及利用微生物組科學的益生元和益生菌療法）。在制酸劑中，氫氧化鋁、碳酸鈣、氫氧化鎂、碳酸氫鈉和製劑的差異會影響製劑策略、患者耐受性考量和市場定位。止瀉藥大致分為吸附劑和鴉片類衍生物。吸附劑包括次水楊酸鉍和高嶺土果膠，而鴉片類衍生物包括地芬諾酯、阿托品和洛哌丁胺等藥物，每種藥物都有其獨特的安全性和監管特性。根據作用機制，止吐藥可進一步分為多巴胺拮抗劑、NK1受體拮抗劑和5-羥色胺受體拮抗劑。在這些類別中，甲氧氯普胺、丙氯拉Aprepitant、阿瑞吡坦、Granisetron、格拉司瓊、Ondansetron和Palonosetron等特定分子影響著關於其臨床定位和處方集的討論。 H2受體拮抗劑包括西咪替丁、法莫替丁、尼扎替丁和雷尼替丁等藥物，而質子幫浦阻斷劑包括Esomeprazole拉唑、蘭索拉唑、奧美拉唑、泮托拉唑和Rabeprazole。每個亞類都有不同的生命週期管理和病患依從性的考量。瀉藥可分為容積性瀉藥、潤滑性瀉藥、滲透性瀉藥、刺激性瀉藥和糞便軟化劑。容積性瀉藥包括甲基纖維素、聚卡波非和車前子，而滲透性瀉藥包括乳果糖、聚乙二醇和山梨醇。這種區分對於臨床指導、患者諮詢以及非處方藥和處方藥的發展趨勢至關重要。益生菌和益生元包括益生元（如果寡糖和菊糖）以及益生菌菌株（如雙歧桿菌、乳酸桿菌和布氏酵母菌）。這些都導致​​了菌株特異性的證據要求和監管途徑。

影響美洲、歐洲、中東和非洲以及亞太地區市場准入、商業化和生產優先事項的區域戰略挑戰。

區域趨勢持續影響企業的產品上市、供應鏈韌性和商業性投資的優先順序。在美洲，支付者和醫療服務提供者日益關注療效、成本控制和真實世界數據（REW），促使製造商加強上市後證據的收集並進行價值論證活動。北美地區的醫院採購流程和專科藥房管道正在影響醫院管理和專科消化器官系統療法的應用模式。同時，拉丁美洲的趨勢要求企業採取適應性定價策略並建立區域製造夥伴關係，以應對准入限制。

製藥公司為加強其產品線而採取的企業策略和戰術性措施，最大限度地延長了消化器官系統藥物的產品生命週期並最佳化了分銷。

胃腸道治療領域的公司正在採取多種策略舉措，以維持成長、確保獲利並提供差異化的臨床價值。擁有成熟產品系列的公司正投資於生命週期管理策略，例如開發新製劑、固定劑量組合藥物和拓展適應症，以在競爭激烈的治療領域中保持領先地位。同時，其他公司則致力於加大研發投入，探索以微生物組為基礎的方法、新型受體標靶和治療平台，以滿足慢性胃腸道疾病領域尚未滿足的醫療需求。

建議製藥公司採取切實可行的跨部門舉措，將證據商業化和供應彈性相結合，以擴大患者用藥範圍並實現競爭差異化。

行業領導企業應優先考慮制定協調一致的議程，將臨床證據的獲取與切實可行的商業性執行和穩健的業務運營相結合。首先，應在研發計劃早期整合基於機制的證據和真實世界數據（RWE）項目，以支持差異化主張並促進與支付方的對話。投資於生物標記主導的臨床試驗和患者報告結局的縱向研究將增強價值提案。其次，應實現原料藥和原料藥籌資策略的多元化，並對替代生產合作夥伴進行認證，以降低區域貿易中斷帶來的風險。此外，應儘早與監管回應團隊接洽，以簡化與生產變更相關的必要申請程序。

調查方法解釋如何透過質性訪談、監管審查和主題綜合分析，得出實用見解，避免投機性的市場預測。

本摘要所依據的研究融合了第一手和第二手調查方法，旨在建構全面平衡的觀點。透過對臨床醫生、處方集決策者、採購經理和行業高管的定性訪談，我們深入了解了產品應用促進因素、供應考量以及支付方趨勢。這些訪談內容與監管指南、臨床文獻和產品技術資訊進行了交叉核對，以確保臨床和營運方面的準確性。

簡明結論指出，臨床證據、商業策略和營運準備是決定胃腸道藥物產品成功實施的關鍵因素。

總而言之，消化器官系統藥物市場格局正處於轉折點，隨著科學創新、分銷管道的演變和供應韌性的交匯，策略挑戰也不斷重塑。能夠將治療差異化與可靠的實證醫學證據、靈活的籌資策略以及針對特定管道的商業模式相結合的公司，將更有利於滿足監管機構的審查和支付方的期望。跨部門合作以及將真實世界數據（REW）儘早整合到研發計劃中，將加速產品推廣應用，並促進與醫療系統和支付方之間的價值對話。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：胃腸道藥物市場：依產品類型分類

  • 制酸劑
    • 氫氧化鋁
    • 碳酸鈣
    • 組合配方
    • 氫氧化鎂
    • 碳酸氫鈉
  • 止瀉
    • 吸附劑
      • 次水楊酸鉍
      • 高嶺土/果膠
    • 鴉片類衍生物
      • 地芬諾酯阿托品
      • 洛哌丁胺
  • 止吐藥
    • 多巴胺拮抗劑
      • 甲氧氯普胺
      • 丙氯拉嗪
    • NK1受體拮抗劑
      • Aprepitant
      • 福沙普利坦
    • 血清素受體拮抗劑
      • Granisetron
      • Ondansetron
      • Palonosetron
  • H2受體拮抗劑
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 瀉藥
    • 容積性瀉藥
      • 甲基纖維素
      • 聚卡波非
      • 螢光棒
    • 潤滑劑
    • 滲透壓
      • 乳果糖
      • 聚乙二醇
      • 山梨醇
    • 刺激性瀉藥
    • 軟便劑
  • 益生菌和益生元
    • 益生元
      • 果寡糖
      • 菊糖
    • 益生菌
      • 雙歧桿菌
      • 乳酸桿菌
      • 布拉氏酵母
  • 質子幫浦阻斷劑
    • Esomeprazole
    • 蘭索拉唑
    • 奧美拉唑
    • 泮托拉唑
    • Rabeprazole

第9章：胃腸道藥物市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
    • 博拉斯注射
    • 靜脈注射
  • 口服
    • 膠囊
    • 液態糖漿
    • 粉末
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 栓劑

第10章：胃腸道藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：胃腸道藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：胃腸道藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：胃腸道藥物市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國胃腸道藥物市場

第15章：中國胃腸藥物市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • American Health
  • Amway Corporation
  • Archer-Daniels-Midland Company
  • ARKOPHARMA Laboratories, Company Limited
  • Bayer AG
  • Biomedical Research Laboratories, LLC
  • DuPont de Nemours, Inc.
  • Dymatize Enterprises LLC
  • FANCL Corporation
  • Glanbia PLC
  • GlaxoSmithKline PLC
  • Herbalife Nutrition Ltd.
  • Himalaya Wellness Company
  • Nature's Sunshine Products, Inc.
  • Nestle SA
  • Nutraceutical International Corporation
  • NutraScience Labs
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Pragati Biocare Pvt. Ltd.,
  • Procter & Gamble Health Limited
  • Pure Encapsulations, LLC.
  • Sabinsa Corporation
  • Sanofi SA
Product Code: MRR-CB04E056533F

The Gastrointestinal Agents Market was valued at USD 63.12 billion in 2025 and is projected to grow to USD 66.15 billion in 2026, with a CAGR of 5.13%, reaching USD 89.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 63.12 billion
Estimated Year [2026] USD 66.15 billion
Forecast Year [2032] USD 89.64 billion
CAGR (%) 5.13%

A concise orienting narrative introducing the current clinical drivers commercial dynamics and strategic priorities shaping gastrointestinal agent development and distribution

The pharmaceutical landscape for gastrointestinal agents is evolving under the combined pressures of changing clinical practice, heightened patient expectations, and rapid scientific progress. This executive summary provides an integrated view of the therapeutic classes, clinical drivers, and commercial dynamics that influence decision making for product development, commercialization, and supply chain management within the GI therapeutic area.

Leading therapeutic categories span acute symptom relief through to long-term management of chronic conditions, and each category has distinct clinical profiles, patient adherence patterns, and regulatory considerations. Stakeholders face the dual challenge of optimizing value for payers and patients while sustaining robust pipelines through targeted innovation. By synthesizing clinical trends, distribution shifts, and regulatory signals, this introduction sets the scene for deeper analysis that follows and prepares readers to interpret strategic recommendations in context.

How scientific advances digital care models regulatory scrutiny and value based payment trends are jointly reshaping therapeutic priorities commercial models and supply chain strategies

The gastrointestinal agents sector is experiencing transformative shifts driven by science, patient expectations, and the evolving healthcare delivery model. Advances in our understanding of the gut microbiome and host-microbe interactions have elevated probiotics, prebiotics, and targeted microbiome therapeutics from niche adjuncts to central elements of therapeutic exploration. Meanwhile, precision medicine approaches are bringing biomarker-guided treatment selection into conversations that previously focused primarily on symptom control.

Concurrently, digital health tools and remote care pathways have reshaped how patients access therapy, adhere to regimens, and report outcomes, prompting manufacturers to integrate digital companion offerings and real-world evidence generation into launch plans. Regulatory attention on long-term safety profiles-particularly for widely used drug classes-has prompted manufacturers to invest in lifecycle management, comparative effectiveness studies, and clinician education initiatives. Supply chain resilience has emerged as a strategic priority, with companies diversifying active pharmaceutical ingredient sourcing and adopting manufacturing redundancy to mitigate disruptions.

Finally, payer emphasis on value and outcomes is accelerating adoption of value-based contracting and indication-specific pricing considerations. Collectively, these shifts converge to favor companies that combine therapeutic innovation with pragmatic commercial models, evidence generation, and agile operations, enabling them to respond to clinician preferences and evolving reimbursement pathways.

Assessing how adjustments in US tariff policy have reshaped sourcing decisions manufacturing resilience and cross functional collaboration across gastrointestinal therapeutic supply chains

The 2025 tariff environment affecting pharmaceutical inputs and finished products has introduced a notable strategic inflection point for industry participants. Tariff adjustments that touch active pharmaceutical ingredients, excipients, packaging components, and finished formulations have influenced procurement decisions, margin management, and sourcing footprints. Companies have responded by reassessing supplier portfolios, accelerating qualification of secondary sources, and increasing buffer inventories to smooth procurement volatility.

Operationally, manufacturers have expanded localization strategies where possible and have diversified contract manufacturing partners to reduce single-point dependencies. These approaches have implications for lead times, quality assurance, and regulatory filings, as establishing new manufacturing relationships often requires additional validation and regulatory engagement. In parallel, procurement teams have renegotiated commercial terms and explored hedging strategies to mitigate input cost swings, while commercial teams have engaged payers and distributors to discuss contract adjustments and shared risk models.

From a clinical supply perspective, the tariff context has elevated the importance of robust demand forecasting and integrated supply-chain planning, particularly for critical hospital-administered therapies and intravenous formulations. Regulatory affairs and quality teams have become more actively involved in sourcing decisions to ensure compliance with product registrations and to manage any changes in manufacturing sites or component provenance. Overall, the tariff landscape has reinforced the need for cross-functional collaboration across sourcing, regulatory, manufacturing, and commercial teams to preserve continuity of care and to protect therapeutic access.

Deep segmentation insight revealing how product type administration route and distribution channel distinctions determine clinical positioning formulation strategy and commercial execution

Segmentation drives targeted strategy and clarifies where clinical differentiation and commercial opportunity intersect. Based on product type, the market spans acute symptom categories such as antacids and anti-emetics, therapeutic classes addressing motility and secretion such as H2 receptor antagonists and proton pump inhibitors, and supportive categories including laxatives alongside prebiotic and probiotic approaches that leverage microbiome science. Within antacids, distinctions between aluminum hydroxide, calcium carbonate, magnesium hydroxide, sodium bicarbonate and combination formulations influence formulation strategy, patient tolerability considerations, and over-the-counter positioning. Anti-diarrheals differentiate into adsorbents and opioid derivatives, with adsorbents encompassing bismuth subsalicylate and kaolin pectin and opioid derivatives represented by agents such as diphenoxylate-atropine and loperamide, each presenting unique safety and regulatory profiles. Anti-emetics are further segmented by mechanism into dopamine antagonists, NK1 receptor antagonists and serotonin receptor antagonists, and within these groups specific molecules like metoclopramide, prochlorperazine, aprepitant, fosaprepitant, granisetron, ondansetron and palonosetron shape clinical positioning and formulary conversations. H2 receptor antagonists include agents such as cimetidine, famotidine, nizatidine and ranitidine, and proton pump inhibitors span esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole, with each subclass presenting distinct lifecycle management and patient adherence considerations. Laxatives subdivide into bulk forming, lubricant, osmotic, stimulant and stool softeners, with bulk forming options such as methylcellulose, polycarbophil and psyllium and osmotic options including lactulose, polyethylene glycol and sorbitol; these distinctions matter for clinical guidance, patient counseling and OTC versus prescription dynamics. Probiotics and prebiotics encompass prebiotics like fructooligosaccharides and inulin alongside probiotic strains including bifidobacterium, lactobacillus and saccharomyces boulardii, which introduce strain-specific evidence requirements and regulatory pathways.

Based on route of administration, differentiation across intramuscular, intravenous, oral and topical routes impacts clinical adoption, formulary placement, and manufacturing complexity. Intravenous therapies require attention to bolus injection and infusion formats, while oral dosage forms such as capsules, liquid syrups, powders and tablets demand varied stability and palatability considerations, and topical options including creams, gels and suppositories have unique patient acceptability and dispensing implications. Distribution channels further shape commercialization approaches, with hospital pharmacy dynamics differing from retail pharmacy and online pharmacy ecosystems in terms of procurement cycles, reimbursement mechanisms and stakeholder engagement. Taken together, segmentation clarifies where clinical evidence, formulation investment and commercial strategy should align to capture therapeutic demand and to manage lifecycle priorities effectively.

Regional strategic imperatives across the Americas Europe Middle East & Africa and Asia Pacific that influence access commercialization and manufacturing priorities

Regional dynamics continue to shape how companies prioritize launches, supply resilience, and commercial investments. In the Americas, payers and providers emphasize outcomes, cost containment and real-world evidence, prompting manufacturers to strengthen post-launch evidence generation and to engage in value demonstration activities. North American hospital procurement processes and specialty pharmacy channels influence adoption patterns for hospital-administered and specialty GI therapies, while Latin American dynamics require adaptive pricing strategies and regional manufacturing partnerships to address access constraints.

Europe, Middle East & Africa present a mosaic of regulatory environments and payer structures that necessitate differentiated market entry playbooks. In several European markets, rigorous health technology assessment processes favor therapies with demonstrable comparative effectiveness and cost-utility evidence, while Middle Eastern markets often prioritize rapid access pathways paired with local registration requirements. African markets pose infrastructure and distribution challenges but also opportunities for strategic partnerships that expand access to essential symptomatic therapies and probiotics.

Asia-Pacific demonstrates a heterogeneous mix of mature markets with advanced regulatory frameworks and emerging markets with significant growth in healthcare access. Regional manufacturing capacity in Asia supports a large portion of global API and formulation output, which in turn affects sourcing strategies for global manufacturers. Patient preferences, regulatory timelines, and distribution models in Asia-Pacific require nuanced engagement strategies, including local clinical collaborations and culturally tailored patient support programs to optimize uptake and adherence.

Corporate strategies and tactical maneuvers adopted by manufacturers to strengthen pipelines maximize product lifecycles and optimize distribution in gastrointestinal therapeutics

Companies across the gastrointestinal therapeutic area are pursuing multiple strategic pathways to sustain growth, protect margins, and deliver differentiated clinical value. Firms with established portfolios are investing in lifecycle management strategies such as new formulations, fixed-dose combinations, and indication expansions to maintain relevance in competitive therapeutic classes. Others are pursuing targeted R&D investments in microbiome-based approaches, novel receptor targets, and therapeutic platforms that address unmet needs in chronic GI disorders.

Strategic alliances and selective in-licensing deals have become prevalent as companies seek to accelerate pipeline diversification without bearing full discovery risk. Contract manufacturing and strategic sourcing partnerships provide scalability while enabling firms to focus internal resources on core competencies such as clinical development and market access. Commercially, manufacturers are refining distribution strategies to balance hospital, retail and online pharmacy channels, deploying channel-specific support programs and digital engagement tools to improve patient adherence and clinician awareness.

Furthermore, companies are enhancing their evidence ecosystems by integrating real-world data collection, patient-reported outcome measures, and pragmatic trial designs into development plans to support payer conversations and to inform guideline updates. Operational excellence initiatives that strengthen quality systems, regulatory readiness and supply-chain visibility remain core to sustaining trust among providers and payers, particularly when therapeutic switching or supply reallocation becomes necessary.

Actionable cross functional initiatives recommended for manufacturers to integrate evidence commercialization and supply resilience to advance patient access and competitive differentiation

Industry leaders should prioritize a coordinated agenda that aligns clinical evidence generation with pragmatic commercial execution and resilient operations. First, integrate mechanistic and real-world evidence programs early in development plans to support differentiated claims and to facilitate payer dialogues; investing in biomarker-driven trials and longitudinal patient-reported outcomes will strengthen value propositions. Second, diversify sourcing strategies for APIs and excipients and qualify alternate manufacturing partners to reduce exposure to regional trade disruptions; include regulatory teams early to streamline any required filings associated with manufacturing changes.

Third, tailor distribution strategies to account for channel-specific behaviors: design hospital engagement plans that emphasize formulary and procurement alignment, craft retail pharmacy initiatives to support OTC and chronic care adherence, and develop digital-first approaches for online pharmacy partnerships that enhance patient convenience and retention. Fourth, adopt modular commercial models that incorporate patient support programs, digital adherence tools, and outcome-based contracting pilots where appropriate to align incentives with payers and providers. Finally, foster cross-functional governance that brings R&D, regulatory, manufacturing, and commercial leadership together under a common roadmap to accelerate decision making and to ensure operational readiness for launches and supply shifts.

Methodological approach explaining how qualitative interviews regulatory review and thematic synthesis produced action oriented insights while avoiding speculative market projections

The research underpinning this summary synthesizes primary and secondary methodologies to build a comprehensive and balanced perspective. Qualitative interviews with clinicians, formulary decision makers, procurement leads and industry executives provided directional insight into adoption drivers, supply considerations and payer dynamics. These interviews were triangulated with regulatory guidance, clinical literature, and technical product information to ensure clinical and operational accuracy.

Analytical processes emphasized thematic synthesis rather than quantitative extrapolation, focusing on decision-relevant findings such as formulation tolerability, route-specific adoption patterns, distribution channel nuances, and strategic sourcing implications. Cross-validation steps included internal expert review and scenario analysis to stress-test assumptions about supply vulnerabilities and commercialization approaches. The methodology deliberately prioritized actionable insight generation and practical recommendations while avoiding speculative market sizing, ensuring that conclusions remain evidence-based and relevant for commercial and clinical stakeholders.

Concise concluding perspective that synthesizes clinical evidence commercial strategy and operational readiness as determinants of successful gastrointestinal product execution

In summary, the gastrointestinal agents landscape is at an inflection point where scientific innovation, distribution evolution and supply resilience converge to redefine strategic imperatives. Companies that align therapeutic differentiation with robust evidence generation, agile sourcing strategies, and channel-specific commercial models will be best positioned to navigate regulatory scrutiny and payer expectations. Cross-functional collaboration and early integration of real-world evidence into development plans will accelerate adoption and support value conversations with health systems and payers.

Operational readiness, particularly in manufacturing and procurement, remains essential to mitigate risks introduced by shifting trade policies and to protect continuity of care. Ultimately, pragmatic execution that translates clinical promise into accessible, affordable therapies will determine success across therapeutic classes and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Agents Market, by Product Type

  • 8.1. Antacids
    • 8.1.1. Aluminum Hydroxide
    • 8.1.2. Calcium Carbonate
    • 8.1.3. Combination Formulations
    • 8.1.4. Magnesium Hydroxide
    • 8.1.5. Sodium Bicarbonate
  • 8.2. Anti Diarrheals
    • 8.2.1. Adsorbents
      • 8.2.1.1. Bismuth Subsalicylate
      • 8.2.1.2. Kaolin Pectin
    • 8.2.2. Opioid Derivatives
      • 8.2.2.1. Diphenoxylate Atropine
      • 8.2.2.2. Loperamide
  • 8.3. Anti Emetics
    • 8.3.1. Dopamine Antagonists
      • 8.3.1.1. Metoclopramide
      • 8.3.1.2. Prochlorperazine
    • 8.3.2. NK1 Receptor Antagonists
      • 8.3.2.1. Aprepitant
      • 8.3.2.2. Fosaprepitant
    • 8.3.3. Serotonin Receptor Antagonists
      • 8.3.3.1. Granisetron
      • 8.3.3.2. Ondansetron
      • 8.3.3.3. Palonosetron
  • 8.4. H2 Receptor Antagonists
    • 8.4.1. Cimetidine
    • 8.4.2. Famotidine
    • 8.4.3. Nizatidine
    • 8.4.4. Ranitidine
  • 8.5. Laxatives
    • 8.5.1. Bulk Forming
      • 8.5.1.1. Methylcellulose
      • 8.5.1.2. Polycarbophil
      • 8.5.1.3. Psyllium
    • 8.5.2. Lubricant
    • 8.5.3. Osmotic
      • 8.5.3.1. Lactulose
      • 8.5.3.2. Polyethylene Glycol
      • 8.5.3.3. Sorbitol
    • 8.5.4. Stimulant
    • 8.5.5. Stool Softeners
  • 8.6. Probiotics & Prebiotics
    • 8.6.1. Prebiotics
      • 8.6.1.1. Fructooligosaccharides
      • 8.6.1.2. Inulin
    • 8.6.2. Probiotics
      • 8.6.2.1. Bifidobacterium
      • 8.6.2.2. Lactobacillus
      • 8.6.2.3. Saccharomyces Boulardii
  • 8.7. Proton Pump Inhibitors
    • 8.7.1. Esomeprazole
    • 8.7.2. Lansoprazole
    • 8.7.3. Omeprazole
    • 8.7.4. Pantoprazole
    • 8.7.5. Rabeprazole

9. Gastrointestinal Agents Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
    • 9.2.1. Bolus Injection
    • 9.2.2. Infusion
  • 9.3. Oral
    • 9.3.1. Capsule
    • 9.3.2. Liquid Syrup
    • 9.3.3. Powder
    • 9.3.4. Tablet
  • 9.4. Topical
    • 9.4.1. Creams
    • 9.4.2. Gels
    • 9.4.3. Suppositories

10. Gastrointestinal Agents Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Gastrointestinal Agents Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Gastrointestinal Agents Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Gastrointestinal Agents Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Gastrointestinal Agents Market

15. China Gastrointestinal Agents Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. American Health
  • 16.7. Amway Corporation
  • 16.8. Archer-Daniels-Midland Company
  • 16.9. ARKOPHARMA Laboratories, Company Limited
  • 16.10. Bayer AG
  • 16.11. Biomedical Research Laboratories, LLC
  • 16.12. DuPont de Nemours, Inc.
  • 16.13. Dymatize Enterprises LLC
  • 16.14. FANCL Corporation
  • 16.15. Glanbia PLC
  • 16.16. GlaxoSmithKline PLC
  • 16.17. Herbalife Nutrition Ltd.
  • 16.18. Himalaya Wellness Company
  • 16.19. Nature's Sunshine Products, Inc.
  • 16.20. Nestle S.A
  • 16.21. Nutraceutical International Corporation
  • 16.22. NutraScience Labs
  • 16.23. Otsuka Holdings Co. Ltd.
  • 16.24. Pfizer Inc.
  • 16.25. Pragati Biocare Pvt. Ltd.,
  • 16.26. Procter & Gamble Health Limited
  • 16.27. Pure Encapsulations, LLC.
  • 16.28. Sabinsa Corporation
  • 16.29. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL AGENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BIFIDOBACTERIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BIFIDOBACTERIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTOBACILLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTOBACILLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SACCHAROMYCES BOULARDII, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SACCHAROMYCES BOULARDII, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SACCHAROMYCES BOULARDII, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PANTOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PANTOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BOLUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BOLUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LIQUID SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LIQUID SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LIQUID SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 249. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
  • TABLE 250. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2032 (USD MILLION)
  • TABLE 251. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2032 (USD MILLION)
  • TABLE 252. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 253. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 260. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 270. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 272. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2032 (USD MILLION)
  • TABLE 274. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 276. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 278. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2032 (USD MILLION)
  • TABLE 288. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 290. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 292. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 294. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2032 (USD MILLION)
  • TABLE 296. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2032 (USD MILLION)
  • TABLE 298. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 300. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 302. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 304. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 306. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINA